Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient: A Case Report

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,14 MB, PDF-dokument

  • Shan Wen Lui
  • Lu, Jeng-Wei
  • Yi Jung Ho
  • Shih En Tang
  • Kai Hsiung Ko
  • Ting Yu Hsieh
  • Feng Cheng Liu

BACKGROUND/AIM: Progressive fibrosing interstitial lung disease (PF-ILD) refers to a group of chronic lung conditions commonly associated with immunoglobulin G4-related disorders. It is characterized by progressive scarring (fibrosis) within the pulmonary interstitium, resulting in respiratory failure and early mortality. Some patients do not respond to standard therapeutic interventions. Numerous studies have confirmed the anti-inflammatory and antioxidant properties of molecular hydrogen in various disease models. CASE REPORT: In this report, we present a case study of an 85-year-old female diagnosed with suspected IgG4-related PF-ILD complicated by hospital-acquired pneumonia. On the fourth day of hydrogen-assisted therapy, a noticeable improvement in lung infiltrations was observed in chest X-rays as the patient gradually progressed towards weaning off mechanical ventilation. To assess treatment responses, we compared immune phenotypes before and after hydrogen treatment. A marked increase was observed in resting regulatory T cell levels after treatment, accompanied by a notable decrease in Fas+ helper T cell and cytotoxic T cell subtypes. CONCLUSION: This case study highlights the effectiveness of hydrogen-assisted therapy in managing PF-ILD complicated by pneumonia, warranting further research in the future.

OriginalsprogEngelsk
TidsskriftIn vivo (Athens, Greece)
Vol/bind38
Udgave nummer3
Sider (fra-til)1512-1518
Antal sider7
ISSN0258-851X
DOI
StatusUdgivet - 2024

Bibliografisk note

Publisher Copyright:
Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

ID: 392918152